News Year None202120202019201820172016201520132012201020092008 January 12, 2021 NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology January 5, 2021 NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock January 4, 2021 NGM Bio Announces Proposed Offering of Common Stock
January 12, 2021 NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
